Free Trial
NASDAQ:BLUE

bluebird bio (BLUE) Stock Price, News & Analysis

bluebird bio logo
$4.97 0.00 (0.00%)
As of 06/2/2025

About bluebird bio Stock (NASDAQ:BLUE)

Key Stats

Today's Range
$4.97
$4.97
50-Day Range
$3.29
$5.00
52-Week Range
$3.20
$28.60
Volume
N/A
Average Volume
440,182 shs
Market Capitalization
$48.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.60
Consensus Rating
Hold

Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

bluebird bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

BLUE MarketRank™: 

bluebird bio scored higher than 43% of companies evaluated by MarketBeat, and ranked 402nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    bluebird bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    bluebird bio has received no research coverage in the past 90 days.

  • Read more about bluebird bio's stock forecast and price target.
  • Earnings Growth

    Earnings for bluebird bio are expected to grow in the coming year, from ($27.25) to ($11.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of bluebird bio is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of bluebird bio is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    bluebird bio has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about bluebird bio's valuation and earnings.
  • Short Interest

    There is no current short interest data available for BLUE.
  • Dividend Yield

    bluebird bio does not currently pay a dividend.

  • Dividend Growth

    bluebird bio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BLUE.
  • News Sentiment

    bluebird bio has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for bluebird bio this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for BLUE on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, bluebird bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.40% of the stock of bluebird bio is held by insiders.

  • Percentage Held by Institutions

    87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about bluebird bio's insider trading history.
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

BLUE Stock Analysis - Frequently Asked Questions

bluebird bio's stock was trading at $8.34 on January 1st, 2025. Since then, BLUE shares have decreased by 40.4% and is now trading at $4.97.
View the best growth stocks for 2025 here
.

bluebird bio, Inc. (NASDAQ:BLUE) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($13.20) earnings per share for the quarter, beating analysts' consensus estimates of ($13.80) by $0.60. The firm's revenue was up 17364.8% on a year-over-year basis.
Read the conference call transcript
.

bluebird bio's stock reverse split before market open on Friday, December 13th 2024.The 1-20 reverse split was announced on Wednesday, December 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that bluebird bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

Last Earnings
11/07/2023
Today
6/30/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
520
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.60
High Stock Price Target
$120.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+797.4%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$211.91 million
Net Margins
-565.74%
Pretax Margin
-551.41%

Debt

Sales & Book Value

Annual Sales
$103.95 million
Price / Cash Flow
N/A
Book Value
$35.59 per share
Price / Book
0.14

Miscellaneous

Free Float
9,586,000
Market Cap
$48.67 million
Optionable
Optionable
Beta
0.27

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:BLUE) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners